Podocytopathy in the mesangial proliferative immunoglobulin A nephropathy: new insights into the mechanisms of damage and progression

2019 ◽  
Vol 34 (8) ◽  
pp. 1280-1285 ◽  
Author(s):  
Hernán Trimarchi ◽  
Rosanna Coppo

Abstract Immunoglobulin A nephropathy (IgAN) was defined as a mesangiopathic disease, since the primary site of deposition of IgA immune material is the mesangium, and proliferation of mesangial cells and matrix excess deposition are the first histopathologic lesions. However, the relentless silent progression of IgAN is mostly due to the development of persistent proteinuria, and recent studies indicate that a major role is played by previous damage of function and anatomy of podocytes. In IgAN, the podocytopathic changes are the consequence of initial alterations in the mesangial area with accumulation of IgA containing immune material. Podocytes are therefore affected by interactions of messages originally driven from the mesangium. After continuous insult, podocytes detach from the glomerular basement membrane. This podocytopathy favours not only the development of glomerular focal and segmental sclerosis, but also the progressive renal function loss. It is still debated whether these lesions can be prevented or cured by corticosteroid/immunosuppressive treatment. We aimed to review recent data on the mechanisms implicated in the podocytopathy present in IgAN, showing new molecular risk factors for progression of this disease. Moreover, these observations may indicate that the target for new drugs is not only focused on decreasing the activity of mesangial cells and inflammatory reactions in IgAN, but also on improving podocyte function and survival.

2008 ◽  
Vol 56 (3) ◽  
pp. 581-586
Author(s):  
Jonathan Bank ◽  
Aharon Ben-David ◽  
Ram Doolman ◽  
Ben-Ami Sela ◽  
Ilan Bank

BackgroundThe α1β1 integrin is a cell surface membrane heterodimer composed of noncovalently linked α1 and β1 polypeptides that is up-regulated on activated and proliferating mesangial cells.MethodsA double-sandwich enzyme-linked immunosorbent assay that detects α1 integrin in a specific and dose-dependent manner at concentrations greater than 150 ng/mL was used to evaluate whether intact α1 polypeptides are secreted in the urine samples of 29 patients with various kidney diseases and in those of 5 healthy individuals.Resultsα1 Integrin was detected in 8 of the 29 patients including 3 of 3 patients with biopsy-proven immunoglobulin A nephropathy and 3 of 3 clinically suspected but non-biopsy-proven immunoglobulin A nephropathy with evidence of active nephritis. No α1 integrins were found in samples of 5 healthy controls.Conclusionsα1 Integrin polypeptides can be detected in human urine, particularly in immunoglobulin A nephropathy. Further extensive studies are required to clarify the significance of secretion of α1 integrins in urine of patients with kidney disease.


2008 ◽  
Vol 51 (5) ◽  
pp. 724-731 ◽  
Author(s):  
Cheuk-Chun Szeto ◽  
Kai-Ming Chow ◽  
Bonnie Ching-Ha Kwan ◽  
Kwok-Yi Chung ◽  
Chi-Bon Leung ◽  
...  

2018 ◽  
Vol 34 (9) ◽  
pp. 1549-1558 ◽  
Author(s):  
Ran Luo ◽  
Shui-Ming Guo ◽  
Yue-Qiang Li ◽  
Yi Yang ◽  
Meng-Lan Li ◽  
...  

Abstract Background A recognized noninvasive biomarker to improve risk stratification of immunoglobulin A nephropathy (IgAN) patients is scarce. Fractalkine has been shown to play a key role in glomerular disease as chemoattractant, adhesion and even fibrosis factor. The current study assessed the possibility of plasma fractalkine as a novel biomarker in IgAN patients. Methods Plasma fractalkine was measured in 229 patients with renal biopsy consistent IgAN from 2012 to 2014, and clinical, pathological and prognostic relationships were analyzed. Results The plasma fractalkine levels in IgAN patients were significantly correlated with the creatinine level and 24-h urine protein by both univariate and multivariate analysis. Mesangial hypercellularity was still significantly correlated with the plasma fractalkine levels even after adjustment for other potential predictor variables by multivariate analysis. In addition, the counts of CD20+ B cells or CD68+ macrophage in renal biopsies of IgAN patients were significantly correlated with the plasma fractalkine levels, but not CD4+ and CD8+ T cells. Finally, we concluded that patients with higher plasma fractalkine levels had higher risk of poor renal outcome compared with those with lower plasma fractalkine levels. No association was observed between the CX3CR1 polymorphisms and clinical parameters including plasma fractalkine levels and prognosis. Recombinant fractalkine induced mesangial cells extracellular matrix synthesis and promoted the migration of microphage cells RAW264.7. Conclusions Plasma fractalkine levels were associated with creatinine level, 24-h urine protein, mesangial hypercellularity pathological damage, the CD68+ macrophage and CD20+ B cell infiltration in renal tissue and renal outcome in IgAN patients. Plasma fractalkine might be a potential prognosis novel predictor in Chinese patients with IgAN.


Author(s):  
Richard J. Glassock ◽  
Grace Lee

The term immunoglobulin A nephropathy (IgA nephropathy or IgA N) refers to a primary glomerular disease characterized by the dominant or co-dominant, diffuse, and generalized mesangial deposition of IgA, often accompanied by deposition of IgG and the C3 component of complement in a similar distribution (Donadio and Grande, 2004; Barratt and Feehally, 2005; Tomino, 2007; Glassock, 2008; Lai, 2008). In the past, it has also been referred to as Berger's disease, to signify the senior author of the original publication describing the disorder that first appeared more than 4 decades ago in September of 1968 (Berger and Hinglais, 1968). IgA N is most likely the commonest primary glomerular disease in the developed world (D’Amico, 1987). The disease is characterized principally by episodic glomerular hematuria often with persistent proteinuria of a variable degree. It usually runs an indolent course, but may lead to end-stage renal disease (ESRD) in about 30–50% of cases after 25 years or more of follow-up.


2020 ◽  
Vol 13 (5) ◽  
pp. 758-767
Author(s):  
Barbara Infante ◽  
Michele Rossini ◽  
Adelaide Di Lorenzo ◽  
Nicola Coviello ◽  
Castellano Giuseppe ◽  
...  

Abstract Glomerulonephritis (GN) is the underlying cause of end-stage renal failure in 30–50% of kidney transplant recipients. It represents the primary cause of end-stage renal disease for 25% of the dialysis population and 45% of the transplant population. For patients with GN requiring renal replacement therapy, kidney transplantation is associated with superior outcomes compared with dialysis. Recurrent GN was previously considered to be a minor contributor to graft loss, but with the prolongation of graft survival, the effect of recurrent disease on graft outcome assumes increasing importance. Thus the extent of recurrence of original kidney disease after kidney transplantation has been underestimated for several reasons. This review aims to provide updated knowledge on one particular recurrent renal disease after kidney transplantation, immunoglobulin A nephropathy (IgAN). IgAN is one of the most common GNs worldwide. The pathogenesis of IgAN is complex and remains incompletely understood. Evidence to date is most supportive of a several hit hypothesis. Biopsy is mandatory not only to diagnose the disease in the native kidney, but also to identify and characterize graft recurrence of IgAN in the kidney graft. The optimal therapy for IgAN recurrence in the renal graft is unknown. Supportive therapy aiming to reduce proteinuria and control hypertension is the mainstream, with corticosteroids and immunosuppressive treatment tailored for certain subgroups of patients experiencing a rapidly progressive course of the disease with active lesions on renal biopsy and considering safety issues related to infectious complications.


2021 ◽  
Vol 11 ◽  
Author(s):  
Jingkui Wu ◽  
Qisheng Lin ◽  
Shu Li ◽  
Xinghua Shao ◽  
Xuying Zhu ◽  
...  

Immunoglobulin A nephropathy (IgAN) is a known cause of end-stage kidney disease, but the pathogenesis and factors affecting prognosis are not fully understood. In the present study, we carried out weighted gene correlation network analysis (WGCNA) to identify hub genes related to the occurrence of IgAN and validated candidate genes in experiments using mouse mesangial cells (MMCs) and clinical specimens (kidney tissue from IgAN patients and healthy controls). We screened the GSE37460 and GSE104948 differentially expressed genes common to both datasets and identified periostin (POSTN) as one of the five key genes using the cytoHubba plugin of Cytoscape software and by receiver-operating characteristic curve analysis. The top 25% of genes in the GSE93798 dataset showing variable expression between IgAN and healthy tissue were assessed by WGCNA. The royalblue module in WGCNA was closely related to creatinine and estimated glomerular filtration rate (eGFR) in IgAN patients. POSTN had very high module membership and gene significance values for creatinine (0.82 and 0.66, respectively) and eGFR (0.82 and −0.67, respectively), indicating that it is a co-hub gene. In MMCs, POSTN was upregulated by transforming growth factor β1, and stimulation of MMCs with recombinant POSTN protein resulted in an increase in the level of proliferating cell nuclear antigen (PCNA) and a decrease in that of B cell lymphoma-associated X protein, which were accompanied by enhanced MMC proliferation. POSTN gene knockdown had the opposite effects. Immunohistochemical analysis of kidney tissue specimens showed that POSTN and PCNA levels were elevated, whereas the rate of apoptosis was reduced in IgAN patients relative to healthy controls. POSTN level in the kidney tissue of IgAN patients was positively correlated with creatinine level and negatively correlated with eGFR. Thus, POSTN promotes the proliferation of MCs to promote renal dysfunction in IgAN.


2021 ◽  
Vol 12 ◽  
Author(s):  
Meiying Chang ◽  
Bin Yang ◽  
Liusheng Li ◽  
Yuan Si ◽  
Mingming Zhao ◽  
...  

Modified Huangqi Chifeng decoction (MHCD) has been used to reduce proteinuria in immunoglobulin A nephropathy (IgAN) for many years. Previously, we have demonstrated its protective role in glomerular mesangial cells. Podocyte injury, another key factor associated with proteinuria in IgAN, has also attracted increasing attention. However, whether MHCD can reduce proteinuria by protecting podocytes remains unclear. The present study aimed to investigate the protective effects of MHCD against podocyte injury in a rat model of IgAN. To establish the IgAN model, rats were administered bovine serum albumin, carbon tetrachloride, and lipopolysaccharide. MHCD in three doses or telmisartan was administered once daily for 8 weeks (n = 10 rats/group). Rats with IgAN developed proteinuria at week 6, which worsened over time until drug intervention. After drug intervention, MHCD reduced proteinuria and had no effect on liver and kidney function. Furthermore, MHCD alleviated renal pathological lesions, hyperplasia of mesangial cells, mesangial matrix expansion, and podocyte foot process fusion. Western blot analysis revealed that MHCD increased the expression of the podocyte-associated proteins nephrin and podocalyxin. Additionally, we stained podocyte nuclei with an antibody for Wilms’ tumor protein one and found that MHCD increased the podocyte number in rats with IgAN. In conclusion, these results demonstrate that MHCD attenuates proteinuria by reducing podocyte injury.


2019 ◽  
Author(s):  
Lingzhi Wu ◽  
Di Liu ◽  
Guochun Chen ◽  
Yu Liu ◽  
Jing You ◽  
...  

Abstract Background C3 deposits are widely detected in patients with immunoglobulin A nephropathy (IgAN). However, the relationship between the location and intensity of the C3 deposition and prognosis of IgAN is uncertain. Methods 244 patients diagnosed with IgAN were enrolled in our study during 2010- 2016. Patients were divided into groups according to the location of C3 deposits: mesangial area only versus mesangial area and glomerular capillary loops. We also divided those patients into 4 groups according to the intensity of C3 deposition at the base of location. Renal outcomes were end-stage renal disease(ESRD)or a ≥50% reduction in estimated glomerular filtration rate(eGFR), performed by Kaplan–Meier analysis and Cox proportional hazards models. Results Among the 244 recruited patients with IgAN, 139(56.97%) were female. Compared to patients with C3 deposition in the mesangial area only, those with C3 deposition in the mesangial area and glomerular capillary loops had significantly older, lower levels of serum albumin and eGFR, higher levels of uric acid (UA), severe proteinuria, more intense C3 deposits, were more prone to receive corticosteroids and immunosuppression. There were no other significant differences between C3 deposition in the mesangial area only (≤2+ in intensity) group and C3 deposition in the mesangial area and glomerular capillary loops (≤2+ in intensity) group except for age. Patients in C3 deposition in the mesangial area and glomerular capillary loops (>2+ in intensity) group were associated with lower levels of serum albumin, serum IgG and eGFR, higher levels of serum IgM, UA and blood urea nitrogen (BUN),heavier proteinuria and higher interstitial fibrosis/tubular atrophy scores than C3 deposition in the mesangial area deposits only(>2+ in intensity) group. After a median follow-up of 41.86 months,28(11.48%) patients reached the renal outcomes. Higher intensity of C3 deposition in the mesangial area and glomerular capillary loops (95%CI:1.262-76.832, p=0.029) remained an independent risk factor of renal outcomes by multivariate Cox proportional hazards models. Conclusions IgAN patients who had glomerular capillary loops C3 deposits had worse clinical outcomes. Furthermore, the effect of the C3 deposition site on IgA nephropathy is affected by the intensity of C3 deposits.


Sign in / Sign up

Export Citation Format

Share Document